Ultra Market Research | United Kingdom Vinorelbine Market
United Kingdom Vinorelbine Market
Report ID : 973
Category : Therapeutic-Area,United-Kingdom(UK)
No Of Pages : 95
Published on: January 2025
Status: Published
Format :
Key Question Answer
Global Market Outlook
In-depth analysis of global and regional trends
Analyze and identify the major players in the market, their market share, key developments, etc.
To understand the capability of the major players based on products offered, financials, and strategies.
Identify disrupting products, companies, and trends.
To identify opportunities in the market.
Analyze the regional penetration of players, products, and services in the market.
Comparison of major players financial performance.
Evaluate strategies adopted by major players.
Recommendations
United Kingdom Vinorelbine Market Introduction United Kingdom Vinorelbine Market encompasses production, distribution, and use of vinorelbine-a semi-synthetic chemotherapeutic agent used predominantly in oncology. The drugs are used most for the treatment of NSCLC and breast cancer. Recently, there is a trend of using oral formulations of vinorelbine to enhance compliance by patients and avoid frequent visits to hospitals. The UK vinorelbine market was valued at around GBP 75 million in 2024. The market is expected to grow steadily with advancements in oncology therapeutics, increased prevalence of cancer, and growing healthcare expenditure. The market is competitive, with players focusing on improved formulations and cost-effectiveness.
Segmentation By Formulation • Injectable Vinorelbine o Prefilled Syringes o Vials o Others • Oral Vinorelbine o Capsules o Tablets o Others
By Application • Non-Small Cell Lung Cancer (NSCLC) o Stage I-II o Stage III-IV o Others • Breast Cancer o Metastatic Breast Cancer o Hormone Receptor-Positive Cancer o Others • Other Cancer Types o Ovarian Cancer o Prostate Cancer
By Distribution Channel • Hospital Pharmacies o Public Hospitals o Private Hospitals • Retail Pharmacies o Urban Pharmacies o Rural Pharmacies • Online Pharmacies o Direct-to-Consumer Portals o Third-Party Portals
List of Market Players 1. Roche Holding AG (Switzerland) 2. Teva Pharmaceutical Industries Ltd. (Israel) 3. Sandoz International GmbH (Germany) 4. Pfizer Inc. (United States) 5. Hikma Pharmaceuticals PLC (United Kingdom) 6. Mylan N.V. (United States) 7. Fresenius Kabi AG (Germany) 8. Accord Healthcare (United Kingdom) 9. Lupin Limited (India) 10. Cipla Limited (India) 11. Glenmark Pharmaceuticals (India) 12. Sanofi S.A. (France) 13. Intas Pharmaceuticals Ltd. (India) 14. Dr. Reddy’s Laboratories (India) 15. Apotex Inc. (Canada)
Drivers An increased cancer prevalence now accounting for more than 376,000 new cases every year in the UK, the market demand of the United Kingdom Vinorelbine Market is primarily supported by these statistics. The increasing need for patient-friendly and cost-effective cancer treatments has been a major driving factor in the adoption of oral vinorelbine formulations; technological advancements in drug delivery systems, additionally, are boosting market growth. Positive support from government policies, increased health expenditure, and awareness about early cancer detection have driven the market upward.
Restraints Despite the growth prospects, the market is facing difficulties such as the unaffordable price of vinorelbine formulations in certain patient groups. The stringent regulatory environment of the UK often prolongs the process of drug approvals, which does not allow newer formulations to easily enter the market. Neutropenia and gastrointestinal adverse effects further discourage patients from seeking treatment. Additionally, intense competition from biosimilars and other emerging therapies threatens market growth.
Opportunity Personalized medicine is an opportunity for the United Kingdom Vinorelbine Market. There are opportunities for innovation in formulations and expanded indications due to the cooperation of pharmaceutical companies, research institutions, and healthcare providers. There is potential to increase access to drugs with the growth of telemedicine and online pharmacy platforms. Other growth avenues include ongoing clinical trials using vinorelbine in combination with immunotherapy for resistant cancer types.
Trend Latest trend in the UK Vinorelbine Market is sustainability in the production of pharmaceuticals. Firms are moving towards the eco-friendly manufacture of drugs in order to decrease carbon footprint. Another thing that's taking shape of the market is digital transformation in healthcare. For example, AI-driven drug discovery and predictive analytics are driving forces in this domain. Further, combination therapies, including vinorelbine along with newer agents like checkpoint inhibitors, are becoming the game-changer in oncology treatment protocols.
Approved Products and Pipeline • Approved Products: o Navelbine (Vinorelbine Tartrate) o Vinorelbine Actavis o Vinorelbine Hospira • Pipeline/Reg/Pre-Reg Products: o Oral Vinorelbine XR o Combination with PD-L1 inhibitors o Targeted Liposomal Vinorelbine
The market is growing at a CAGR of approximately 5.2%.
It is primarily used to treat non-small cell lung cancer and breast cancer.
Roche, Pfizer, and Hikma Pharmaceuticals are key players.
High costs, regulatory delays, and competition from biosimilars.
AI in drug discovery and the rise of oral formulations are key technological advancements.
1. Introduction 1.1 Report Description 1.2 Research Methodology 1.2.1 Data Mining 1.2.2 Market Modeling and Forecasting 1.2.3 Data Validation 1.2.4 Industry Analysis
2. Market Dashboard
3. Market Overview 3.1 Market Definition and Scope 3.2 Market Segmentation 3.2.1 By Formulation o Injectable Vinorelbine Prefilled Syringes Vials Others o Oral Vinorelbine Capsules Tablets Others 3.2.2 By Application o Non-Small Cell Lung Cancer (NSCLC) Stage I-II Stage III-IV Others o Breast Cancer Metastatic Breast Cancer Hormone Receptor-Positive Cancer Others o Other Cancer Types Ovarian Cancer Prostate Cancer 3.2.3 By Distribution Channel o Hospital Pharmacies Public Hospitals Private Hospitals o Retail Pharmacies Urban Pharmacies Rural Pharmacies o Online Pharmacies Direct-to-Consumer Portals Third-Party Portals 3.3 Market Dynamics 3.3.1 Drivers 3.3.2 Restraints 3.3.3 Opportunities 3.3.4 Challenges
4. United Kingdom Vinorelbine Market by Formulation 4.1 Introduction 4.2 Market Size and Growth Rate by Formulation (2024-2030) 4.2.1 Injectable Vinorelbine o Prefilled Syringes o Vials o Others 4.2.2 Oral Vinorelbine o Capsules o Tablets o Others
5. United Kingdom Vinorelbine Market by Application 5.1 Introduction 5.2 Market Size and Growth Rate by Application (2024-2030) 5.2.1 Non-Small Cell Lung Cancer (NSCLC) o Stage I-II o Stage III-IV o Others 5.2.2 Breast Cancer o Metastatic Breast Cancer o Hormone Receptor-Positive Cancer o Others 5.2.3 Other Cancer Types o Ovarian Cancer o Prostate Cancer
6. United Kingdom Vinorelbine Market by Distribution Channel 6.1 Introduction 6.2 Market Size and Growth Rate by Distribution Channel (2024-2030) 6.2.1 Hospital Pharmacies o Public Hospitals o Private Hospitals 6.2.2 Retail Pharmacies o Urban Pharmacies o Rural Pharmacies 6.2.3 Online Pharmacies o Direct-to-Consumer Portals o Third-Party Portals
7. Competitive Landscape 7.1 Company Profiles 7.1.1 Roche Holding AG (Switzerland) 7.1.2 Pfizer Inc. (United States) 7.1.3 Sandoz International GmbH (Germany) 7.1.4 Accord Healthcare (United Kingdom) 7.1.5 Hikma Pharmaceuticals PLC (United Kingdom) 7.1.6 Teva Pharmaceutical Industries Ltd. (Israel) 7.1.7 Mylan N.V. (United States) 7.1.8 Lupin Limited (India) 7.1.9 Fresenius Kabi AG (Germany) 7.1.10 Sanofi S.A. (France) 7.1.11 Glenmark Pharmaceuticals (India) 7.1.12 Intas Pharmaceuticals Ltd. (India) 7.1.13 Dr. Reddy’s Laboratories (India) 7.1.14 Cipla Limited (India) 7.1.15 Apotex Inc. (Canada)
8. Conclusion and Recommendations
9. Appendix 9.1 List of Tables o Table 1: Market Segmentation by Formulation o Table 2: Market Segmentation by Application o Table 3: Market Segmentation by Distribution Channel o Table 4: Competitive Landscape Overview
9.2 List of Figures o Figure 1: United Kingdom Vinorelbine Market Size (2024-2030) o Figure 2: Growth Drivers in the Market o Figure 3: Market Share by Application in 2024 o Figure 4: Competitive Analysis by Key Players
Research Methodology
The process of market research at Ultra Market Research is an iterative in application and usually follows following path. Information from secondary used to build data models, then results from data models are validated from primary participants. Then cycle repeats where, according to inputs from primary participants, additional secondary research is done, and new Information is again incorporated into data model. The process continues till desired level of Information is not generated
To calculate the market size, the report considers the revenue generated from the sales of Ultra Market Research providers. The revenue generated from the sales of Ultra Market Research has been calculated through primary and secondary research. The report also presents the key players operating in the Ultra Market Research market across the globe identified through secondary research and a corresponding detailed analysis of the top vendors in the market. The market size calculation also includes distribution channel segmentation determined using secondary sources and verified through primary sources.
Secondary Research
The secondary research source that are typically referred to include, but are not limited to:
Company websites, annual reports, financial reports, broker reports, investor presentations and SEC filings
Internal and external proprietary databases, relevant patent and regulatory databases
National government documents, statistical databases and market reports
News articles, press releases and web-casts specific to the companies operating in the market
The source for secondary research includes but is not limited to: Factiva, Hoovers and Statista
Inner Circle Represents – Stage of Research Process
Middle Circle Represents – Source of Information
Outer Circle Represents – Information Derived from that source
Primary Research We conduct primary interviews on an ongoing basis with industry participants and commentators in order to validate data and analysis. A typical research interview fulfills the following functions:
It provides first-hand Information on the market size, market trends, growth trends, competitive landscape, future outlook etc.
Helps in validating and strengthening the secondary research findings
Further develops the analysis team’s expertise and market understanding
Primary research involves E-mail interactions, telephonic interviews as well as face-to-face interviews for each market, category, segment and sub-segment across geographies
The participants who typically take part in such a process include, but are not limited to:
Industry participants: CEOs, VPs, marketing/ distribution channel managers, market intelligence managers and national sales managers
Purchasing managers, technical personnel, distributors and resellers
Outside experts: Investment bankers, valuation experts, research analysts specializing in specific markets
Key opinion leaders specializing in different areas corresponding to different industry distribution channels
Models Where no hard data is available, we use modeling and estimates in order to produce comprehensive data sets. A rigorous methodology is adopted in which the available hard data is cross referenced with the following data distribution channels to produce estimates:
Demographic data: Population split by segment
Macro-economic indicators: GDP, etc.
Industry indicators: Expenditure, distribution channel stage & infrastructure, sector growth and facilities.
Data is then cross checked by the expert panel.
2..1 Company Share Analysis Model
Company share analysis is used to derive the size of United Kingdom market. As well as study of revenues of companies for last three to five years also provide the base for forecasting the market size and its growth rate. This model is built in following steps: 2..2 Revenue Based Modeling
Revenue based models can be built in two ways – Top-Down or Bottom-Up irrespective of industry. Market size estimated from company share analysis acts as a validation point for bottom-up approach where as it acts as starting point for top-down approach.
2.1 Research Limitations Inflation is not a part of pricing in this report. Prices of United Kingdom Vinorelbine Market and its derivatives vary in each region and hence similar revenue ratio does not follow for each individual region. The same price for each distribution channel has been taken into account while estimating and forecasting market revenue Globally. Regional average price has been considered while breaking down this market by application in each region. This report provides market size of United Kingdom Vinorelbine Market for the past year and forecasts for the next six years. United Kingdom Vinorelbine Market size is given in terms of revenue. Market revenue is defined in USD Million. Market numbers are given on the basis of different United Kingdom Vinorelbine Market categories. Market size and forecasts for each major application is provided in the context of Global market. The numbers provided in this report are derived on the basis of demand for United Kingdom Vinorelbine Market from different application industries in different regions.
Segmentation By Formulation • Injectable Vinorelbine o Prefilled Syringes o Vials o Others • Oral Vinorelbine o Capsules o Tablets o Others
By Application • Non-Small Cell Lung Cancer (NSCLC) o Stage I-II o Stage III-IV o Others • Breast Cancer o Metastatic Breast Cancer o Hormone Receptor-Positive Cancer o Others • Other Cancer Types o Ovarian Cancer o Prostate Cancer
By Distribution Channel • Hospital Pharmacies o Public Hospitals o Private Hospitals • Retail Pharmacies o Urban Pharmacies o Rural Pharmacies • Online Pharmacies o Direct-to-Consumer Portals o Third-Party Portals